A Specific LC-ESI-MS/MS Method Development and Validation for the Quantification of Saquinavir in Biological Matrices
Introduction: Saquinavir is the first protease inhibitor. Proteases are enzymes that cleave protein molecules into smaller fragments. No analytical procedure was reported for the estimation of saquinavir by LC-MS/MS. Aims: The objective of the present research was to develop a specific liquid chromatography-electrospray ionization tandem mass spectrometric technique for the quantitation of saquinavir in biological matrices. Methodology: Chromatographic elution was attained thru a Thermo Hypersil ODS stationary column having the dimensions of 50 × 4.6 mm and particle size of 2.4 μm. Isocratic elution was processed with methanol and 0.1%V/V formic acid in the ratio of 90:10 V/V as mobile phase with flow rate of 0.50 ml/min. Liquid-liquid extraction was performed for drug and internal standard isolation with an ethyl acetate solvent. Parent and productions were monitored at m/z 671.3 → 654.3 for saquinavir and 614.3 → 596.3 for indinavir internal standardon multiple reaction monitoring. Result: Linearity graph of drug was rectilinear in concentration over 260.4. to 10416ng/ml having r2(correlation coefficient) value more than 0.999. Percentage of RSD findings were ≤5.3% for inter and intraday accuracy and precision. This procedure has good recoveries and %recovery findings of lower quality control (LQC), median quality control (MQC) and higher quality control (HQC) samples were 94.6%, 92.4 and 104.2% respectively. Conclusion: Saquinavir has more stability for longer time when subjected for different stability environments and the technique was effectively relevant to routine analysis of saquinavir in biological matrix.
-
Invirase (saquinavir mesylate) Capsules and Tablets, for Oral Use. Full Prescribing Information (PDF). Genentech, Inc. Archived (PDF) from the original on 24 November 2015. Retrieved 23 November 2015.
-
Saquinavir. The American Society of Health-System Pharmacists. Archived from the original on 2015-09-08. Retrieved Sep 5, 2015.
-
Minor, Lisa K. Handbook of Assay Development in Drug Discovery. Hoboken: CRC Press; 2006. p. 117.
-
Hamilton, Richart. Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning; 2015. p. 72.
-
Winston A, Back D, Fletcher C. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS. 2006;20(10):1401–6.
-
HIV Surveillance-United States, 1981-2008. Archived from the original on 9 November 2013. Retrieved 8 November 2013.
-
Sankar DG, Kumar JMR, Reddy MVVN. UV spectrophotometric methods for the determination of Saquinavir mesylate and efavirenz. A J of Chem. 2003; 15(3):1856-1858.
-
Riem Ha H, Follath F, Bloemhard Y, Krahenbuhl S. Determination of saquinavir in human plasma by high-performance liquid chromatography. J of Chrom.B. 1997;694:427–433.
-
Ucpinar SD, Stavchansky S. Quantitative determination of saquinavir from Caco-2 cell monolayers by HPLC-UV. High-performance liquid chromatography. Biomed Chromatogr. 2003;17(1):21-25.
-
Takahashi M, Yoshida M, Oki T, Okumura N, Suzuki T, Kaneda T. Conventional HPLC Method Used for Simultaneous Determination of the Seven HIV Protease Inhibitors and Non-nucleoside Reverse Transcription Inhibitor Efavirenz in Human Plasma. Biol. Pharm. Bull. 2005;28(7):1286—1290.
-
Prakash VK, Venkateswara Rao J, Appala Raju N. Estimation of Saquinavir Mesylate in Tablet Dosage Form using RP-HPLC. A J of Chem. 2009;21:612-616.
-
Richard Hoetelmans MW, Marjolijn Van E, Pieter Meenhorst L, Jan Mulder W, Jos Beijnen H. Determination of saquinavir in human plasma, saliva, and cerebrospinal fluid by ion-pair high-performance liquid chromatography with ultraviolet detection. J Chrom. B. 1997; 698:235-241.
-
FDA Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM) May 2001.
-
European Medicines Agency, Guideline on bioanalytical method validation 2011.
-
Henion J, Brewer E, Rule G. Sample Preparation for LC/MS/MS: Knowing the Basic Requirements and the Big Picture of an LC/MS System can Ensure Success in Most Instances. Anal Chem. 1998;70:650A-656A.
-
Chambers EE, Woodcock MJ, Wheaton JP. Systematic development of an UPLC–MS/MS method for the determination of tricyclic antidepressants in human urine. J. Pharm. Biomed. Anal. 2014;88:660–665.
-
Patel DS, Sharma N, Patel MC. Development and validation of a selective and sensitive LC–MS/MS method for determination of cycloserine in human plasma: application to bioequivalence study, J Chromatogr B. 2011; 879:2265–2273.
-
Hindu K, Vinodhini C, Srinivas SK, Rajan SM, Chitra K, Mangathayaru K. Validated RP-HPLC Method for Quantification of Paclitaxel in Human Plasma – Eliminates Negative Influence of Cremophor EI. IJCRR. 2018;10(13):5-10.
-
Murphy AT, Kasper SC, Gillespie TA, DeLong AF. Determination of Xanomeline and Active Metabolite, N-Desmethylxanomeline, in Human Plasma by Liquid Chromatography-Atmospheric Pressure Chemical Ionization Mass Spectrometry. J. Chromatogr B. Biomed Appl. 1995;668:273-280.
-
Nagalakshmi V, Srinivas Rao G, Gayathri Devi N, Mohan S. RP-HPLC Method for Simultaneous Estimation of Vildagliptin and Metformin in Bulk and Pharmaceutical Formulations. IJCRR. 2021. 13(7)112-117.
-
Cheruku S, Bhikshapathi DVRN. Validation of a specific LC-MS/MS method for the quantification of anti-cancer alectinib in biological matrices. IJPR. 2021;13(1):6513-21.